Clinical Trial Update: Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) [Phase 2]

View source ↗

Summary

A Phase 2 trial in China is evaluating an anti-CD38 monoclonal antibody in combination with rituximab for primary immune thrombocytopenia and is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Anti-CD38 monoclonal antibody (CD38-directed monoclonal antibody)
• Rituximab (rituximab)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Immune Thrombocytopenia, Treatment | Phase 2 | Status: RECRUITING